Kestra Medical Technologies (NASDAQ:KMTS) CFO Sells $128,305.80 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) CFO Vaseem Mahboob sold 5,391 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $23.80, for a total transaction of $128,305.80. Following the completion of the sale, the chief financial officer owned 93,891 shares of the company’s stock, valued at $2,234,605.80. This represents a 5.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Vaseem Mahboob also recently made the following trade(s):

• On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.61, for a total value of $199,352.37.
• On Thursday, July 30th, Vaseem Mahboob sold 3,980 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.75, for a total value of $90,545.00.

Kestra Medical Technologies Stock Performance

Shares of NASDAQ KMTS opened at $25.06 on Thursday. The business’s 50-day simple moving average is $22.78 and its 200-day simple moving average is $22.52. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. Kestra Medical Technologies, Ltd. has a 52 week low of $14.10 and a 52 week high of $30.00. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of -10.36 and a beta of 0.58.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The company had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. As a group, equities research analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kestra Medical Technologies

Several hedge funds have recently made changes to their positions in KMTS. Farther Finance Advisors LLC acquired a new stake in Kestra Medical Technologies during the fourth quarter worth about $31,000. Russell Investments Group Ltd. increased its position in shares of Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Kestra Medical Technologies by 148.9% in the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after purchasing an additional 1,638 shares in the last quarter. Daiwa Securities Group Inc. bought a new position in Kestra Medical Technologies in the fourth quarter worth $72,000. Finally, Brown Brothers Harriman & Co. increased its holdings in Kestra Medical Technologies by 26.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after buying an additional 656 shares during the period.

Analysts Set New Price Targets

KMTS has been the topic of a number of research analyst reports. BTIG Research raised their target price on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Wall Street Zen cut shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. The Goldman Sachs Group lowered their price target on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Oppenheimer initiated coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating for the company. Finally, Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a report on Wednesday, July 15th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kestra Medical Technologies presently has a consensus rating of “Hold” and a consensus target price of $27.83.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.